Arcutis Q4 2022 net loss $72M; ZORYVE revenue $3M in first full quarter

Arcutis Biotherapeutics, Inc.

2022-FY EPS reported -$5.66 revenue$3,686,000

Net product revenue for ZORYVE was $3.0M in Q4 2022, first full quarter since August 2022 launch.
Net loss of $72.0M ($1.18/share) in Q4 2022 vs $71.3M ($1.42/share) in Q4 2021.
Full-year 2022 net loss $311.5M ($5.66/share) vs $206.4M ($4.18/share) in 2021.
Cash, equivalents, and marketable securities $410.8M as of Dec 31, 2022.
Positive Phase 3 atopic dermatitis results; NDA submitted for roflumilast foam in seborrheic dermatitis.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcutis Biotherapeutics, Inc. reported the year ended December 31, 2022 results: revenue $3.7 million.

Period: the year ended December 31, 2022
Revenue: $3.7 million
Result: reported results

Exact text from the filing

Net product revenues for the year ended December 31, 2022 were $3.7 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcutis Biotherapeutics, Inc. reported the quarter ended December 31, 2022 results: revenue $3.0 million.

Period: the quarter ended December 31, 2022
Revenue: $3.0 million
Result: reported results

Exact text from the filing

Net product revenues for the quarter ended December 31, 2022 related to sales of ZORYVE were $3.0 million driven by unit demand.

View on SEC.gov

Browse all earnings releases →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.